Name: CheckMate 744

About this trial

The purpose of this study is to determine whether nivolumab + brentuximab vedotin, followed by brentuximab vedotin + bendamustine for participants with a suboptimal response, is safe and effective in the treatment of classic Hodgkin lymphoma (cHL) in children, adolescents, and young adults after failure of first line therapy.

Eligible patients from 5 Years to 30 Years will be enrolled in this study.

Patient Profile

Children, adolescents, and young adults with Classic Hodgkin Lymphoma whose disease has come back or did not respond to initial treatment.

Where’s this trial being run?

Crumlin Children’s Hospital and St James’s Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

Print this page

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

Summary Data

Name:	CheckMate 744
Number:	17-07
Full Title:	Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response.

Principal Investigator:	Dr Larry Bacon (St. James's Hospital)
Type:	Industry Sponsored
Sponsor:	Bristol-Myers Squibb
Recruitment Started:	Global: March 2017 Ireland: May 2017

Global Recruitment Target:	80
Ireland Recruitment Target:	2